SAN MATEO, Calif., Jan. 08, 2026 (GLOBE NEWSWIRE) -- (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback